Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01993888 · ClinicalTrials.gov registry record · Phase 3
The EVARREST® Fibrin Sealant Patch Liver Study
A Phase 3 study, sponsored by Ethicon.
- Completed
- Registry status
- Phase 3
- Development phase
- 102
- Enrollment target
NCT01993888 is a Phase 3 study that has completed, run by Ethicon. The registered enrollment target is 102 participants.
The verdict
NCT01993888, a Phase 3 study, has completed, sponsored by Ethicon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 102 participants
- Enrollment target
Study Summary
To evaluate the safety and hemostatic effectiveness of EVARREST® Fibrin Sealant Patch (EVARREST) versus standard of care treatment (SoC) in controlling parenchymal bleeding during hepatic surgery.
Interventions
- BIOLOGICAL EVARREST® Fibrin Sealant Patch
- OTHER Standard of Care (SoC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01993888
The ClinicalTrials.gov registry entry for NCT01993888 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ethicon, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EVARREST® Fibrin Sealant Patch is the first listed.
NCT01993888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01993888 about?
NCT01993888 is a clinical study titled "The EVARREST® Fibrin Sealant Patch Liver Study". To evaluate the safety and hemostatic effectiveness of EVARREST® Fibrin Sealant Patch (EVARREST) versus standard of care treatment (SoC) in controlling parenchymal bleeding during hepatic surgery.
What is the current status of trial NCT01993888?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2013-10. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01993888?
The interventions under investigation include: EVARREST® Fibrin Sealant Patch (BIOLOGICAL), Standard of Care (SoC) (OTHER).
Who is sponsoring clinical trial NCT01993888?
This trial is sponsored by Ethicon, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.